Docality.com Logo
 
Dr. Lyubov  Moysik  Do image

Dr. Lyubov Moysik Do

260 Avenue X
Brooklyn NY 11223
718 368-8855
Medical School: New York College Of Osteo Medicine Of New York Institute Of Technology - 1996
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 211979
NPI: 1053429167
Taxonomy Codes:
207Q00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Lyubov Moysik is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$290.19 Average Price Allowed
By Medicare:
$249.26
HCPCS Code:76770 Description:Us exam abdo back wall comp Average Price:$167.80 Average Price Allowed
By Medicare:
$134.42
HCPCS Code:93925 Description:Lower extremity study Average Price:$234.96 Average Price Allowed
By Medicare:
$215.89
HCPCS Code:G0402 Description:Initial preventive exam Average Price:$186.72 Average Price Allowed
By Medicare:
$171.79
HCPCS Code:93880 Description:Extracranial study Average Price:$231.29 Average Price Allowed
By Medicare:
$217.35
HCPCS Code:93970 Description:Extremity study Average Price:$235.01 Average Price Allowed
By Medicare:
$222.10
HCPCS Code:76700 Description:Us exam abdom complete Average Price:$167.94 Average Price Allowed
By Medicare:
$160.50
HCPCS Code:76536 Description:Us exam of head and neck Average Price:$151.45 Average Price Allowed
By Medicare:
$145.49
HCPCS Code:94010 Description:Breathing capacity test Average Price:$48.20 Average Price Allowed
By Medicare:
$42.53
HCPCS Code:69401 Description:Inflate middle ear canal Average Price:$106.84 Average Price Allowed
By Medicare:
$101.92
HCPCS Code:94060 Description:Evaluation of wheezing Average Price:$76.31 Average Price Allowed
By Medicare:
$71.90
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$185.71 Average Price Allowed
By Medicare:
$181.78
HCPCS Code:94690 Description:Exhaled air analysis Average Price:$65.81 Average Price Allowed
By Medicare:
$62.26
HCPCS Code:G0179 Description:MD recertification HHA PT Average Price:$49.32 Average Price Allowed
By Medicare:
$46.77
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$120.08 Average Price Allowed
By Medicare:
$117.57
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$24.50 Average Price Allowed
By Medicare:
$22.11
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$81.56 Average Price Allowed
By Medicare:
$79.77
HCPCS Code:99406 Description:Behav chng smoking 3-10 min Average Price:$16.85 Average Price Allowed
By Medicare:
$15.12
HCPCS Code:G0439 Description:PPPS, subseq visit Average Price:$126.43 Average Price Allowed
By Medicare:
$125.20
HCPCS Code:94640 Description:Airway inhalation treatment Average Price:$22.09 Average Price Allowed
By Medicare:
$21.34
HCPCS Code:83036 Description:Glycosylated hemoglobin test Average Price:$14.15 Average Price Allowed
By Medicare:
$13.67
HCPCS Code:82962 Description:Glucose blood test Average Price:$3.33 Average Price Allowed
By Medicare:
$3.06
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$28.42 Average Price Allowed
By Medicare:
$28.18
HCPCS Code:94664 Description:Evaluate pt use of inhaler Average Price:$20.70 Average Price Allowed
By Medicare:
$20.53
HCPCS Code:36415 Description:Routine venipuncture Average Price:$3.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:81002 Description:Urinalysis nonauto w/o scope Average Price:$3.60 Average Price Allowed
By Medicare:
$3.60
HCPCS Code:G0008 Description:Admin influenza virus vac Average Price:$28.23 Average Price Allowed
By Medicare:
$28.23
HCPCS Code:J1020 Description:Methylprednisolone 20 MG inj Average Price:$1.36 Average Price Allowed
By Medicare:
$1.36
HCPCS Code:J3301 Description:Triamcinolone acet inj NOS Average Price:$1.63 Average Price Allowed
By Medicare:
$1.63
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$14.05 Average Price Allowed
By Medicare:
$14.05

HCPCS Code Definitions

76536
Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation
76700
Ultrasound, abdominal, real time with image documentation; complete
76770
Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93880
Duplex scan of extracranial arteries; complete bilateral study
93925
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study
93970
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study
94010
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
94060
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
94640
Pressurized or nonpressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (eg, with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure breathing [IPPB] device)
94664
Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device
94690
Oxygen uptake, expired gas analysis; rest, indirect (separate procedure)
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99406
Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes
G0008
Administration of influenza virus vaccine
G0179
Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implementation of the plan of care that meets patient's needs, per re-certification period
G0402
Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment
G0439
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
J1020
Injection, methylprednisolone acetate, 20 mg
J3301
Injection, triamcinolone acetonide, not otherwise specified, 10 mg
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1255449229
Diagnostic Radiology
1,182
1679681639
Endocrinology
752
1265445639
Neurology
688
1720050040
Diagnostic Radiology
343
1952399487
Cardiac Surgery
322
1427058858
Neurology
233
1164618708
Diagnostic Radiology
207
1285659649
Diagnostic Radiology
95
*These referrals represent the top 10 that Dr. Moysik has made to other doctors

Publications

Neutral binuclear rare-earth metal complexes with four μ₂-bridging hydrides. - Chemical communications (Cambridge, England)
The first neutral rare-earth metal dinuclear dihydrido complexes [(NPNPN)LnH2]2 (2-Ln; Ln = Y, Lu; NPNPN: N[Ph2PNC6H3((i)Pr)2]2) bearing μ2-bridging hydride ligands have been synthesized. In the presence of THF, 2-Y undergoes intramolecular activation of the sp(2) C-H bond to form dinuclear aryl-hydride complex 3-Y containing three μ2-bridging hydride ligands.
Metallacyclic yttrium alkyl and hydrido complexes: synthesis, structures and catalytic activity in intermolecular olefin hydrophosphination and hydroamination. - Dalton transactions (Cambridge, England : 2003)
Metallacyclic neutral and ionic yttrium alkyl complexes coordinated by a dianionic ene-diamido ligand ([2,6-iPr2C6H3NC(Me)=C(Me)NC6H3iPr2-2,6] = L(1)) [L(1)]Y(CH2SiMe3)(THF)2 (2), {[L(1)]Y(CH2SiMe3)2}(-){Li(THF)4}(+) (3), [L(1)]Y(OEt2)(μ-Me)2Li(TMEDA) (4) were synthesized using a salt-metathesis approach starting from the related chloro complex [L(1)]Y(THF)2(μ-Cl)2Li(THF)2 (1) in 70, 85 and 72% yields respectively. The reactions of 2 with H2 or PhSiH3 afford the dimeric hydride {[L(1)]Y(THF)(μ-H)}2(μ-THF) (5) containing two μ-bridging hydrido and one μ-bridging THF ligands (91 and 85% yields). The X-ray studies of complexes 2, 3 and 5 revealed η(2)-coordination of the C=C fragment of an ene-diamido ligand to a Y cation. DFT calculations were carried out to give an insight into the metal-ligand bonding and especially the interaction between the metal and the ene-diamido ligand. The observed bonding of the ene-diamido fragment is found to reflect the acidity of the metal center in the complex that is partially overcome by a better donation from the double bond (better overlap with an empty d orbital at the yttrium center). The treatment of complex 4 with DME resulted in the C-O bond cleavage of DME and afforded a three nuclear methoxide oxide complex [{[L(1)]Y}3(μ(2)-OMe)3(μ(3)-O)](2-)[Li(DME)3](+)2 (6). Complexes 2, 3, 5 and 7 proved to be efficient precatalysts for the intermolecular hydrophosphination of styrene, 4-vinylpyridine, and 1-nonene with PhPH2 and Ph2PH as well as hydroamination of styrene and pyrrolidine.
Trinuclear alkyl hydrido rare-earth complexes supported by amidopyridinato ligands: synthesis, structures, C-Si bond activation and catalytic activity in ethylene polymerization. - Dalton transactions (Cambridge, England : 2003)
The reaction of Ap(9Me)Lu(CH2SiMe3)2(thf) (Ap(9Me) = (2,4,6-trimethylphenyl)[6-(2,4,6-triisopropylphenyl)pyridine-2-yl]amido ligand) with two molar equivalents of PhSiH3 affords a trinuclear alkyl-hydrido cluster [(Ap(9Me)Lu)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2]. The analogous reactions with Ap(9Me)Ln(CH2SiMe3)2(thf) (Ln = Y, Yb) are more complex and result in the formation of mixtures of two types of trinuclear alkyl-hydrido complexes [(Ap(9Me)Ln)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2] and [(Ap(9Me)Ln)3(μ(2)-H)3(μ(3)-H)2(CH2SiH2Ph)(thf)2] differing in the alkyl group. The DFT calculations of [(Ap*Y)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2] (Ap* = (2,6-diisopropylphenyl)[6-(2,4,6-triisopropylphenyl)pyridine-2-yl]amido ligand) confirm localization of the HOMO on the Ap*-Y(1A)-CH2SiMe3 fragment, thus explaining its enhanced reactivity. Analysis of the electron density distribution reveals the Y-H and H-H bonding interactions in the (Y)3(μ(2)-H)3(μ(3)-H)2 moiety. The NMR studies of diamagnetic complexes [(Ap(9Me)Lu)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2] and [(Ap*Y)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2] demonstrated that the trinuclear cores are retained in the solution and revealed exchange between μ(3)- and μ(2)-bridging hydrido ligands. Complexes [(Ap*Ln)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2], the cationic yttrium hydrido cluster [(Ap*Y)3(μ(2)-H)3(μ(3)-H)2(thf)3](+)[B(C6F5)4](-) as well as [(Ap(9Me)Ln)3(μ(2)-H)3(μ(3)-H)2(CH2SiMe3)(thf)2] proved to be active in catalysis of ethylene polymerization under mild conditions.
Metal-to-ligand alkyl migration inducing carbon-sulfur bond cleavage in dialkyl yttrium complexes supported by thiazole-containing amidopyridinate ligands: synthesis, characterization, and catalytic activity in the intramolecular hydroamination reaction. - Chemistry (Weinheim an der Bergstrasse, Germany)
Neutral Y(III) dialkyl complexes supported by tridentate N(-) ,N,N monoanionic methylthiazole- or benzothiazole-amidopyridinate ligands have been prepared and completely characterized. Studies on their stability in solution revealed progressive rearrangement of the coordination sphere in the benzothiazole-containing system through an unprecedented metal-to-ligand alkyl migration and subsequent thiazole ring opening. Attempts to synthesize hydrido species from the dialkyl precursor led to the generation of a dimeric yttrium species stabilized by a trianionic N(-) ,N,N(-) ,S(-) ligand as the result of metal-to-ligand hydride migration with chemoselective thiazole ring opening and subsequent dimerization through intermolecular addition of the residual YH group to the imino fragment of a second equivalent of the ring-opened intermediate. DFT calculations were used to elucidate the thermodynamics and kinetics of the process, in support of the experimental evidence. Finally, all isolated yttrium complexes, especially their cationic forms prepared by activation with the Lewis acid Ph3 C(+) [B(C6 F5 )4 ](-) , were found to be good candidate catalysts for intramolecular hydroamination/cyclization reactions. Their catalytic performance with a number of primary and secondary amino alkenes was assessed.© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Divalent heteroleptic ytterbium complexes--effective catalysts for intermolecular styrene hydrophosphination and hydroamination. - Inorganic chemistry
New heteroleptic Yb(II)-amide species supported by amidinate and 1,3,6,8-tetra-tert-butylcarbazol-9-yl ligands [2-MeOC6H4NC(tBu)N(C6H3-iPr2-2,6)]YbN(SiMe3)2(THF) (6) and [1,3,6,8-tBu4C12H4N]Yb[N(SiMe3)2](THF)n (n = 1 (7), 2 (8)) were synthesized using the amine elimination approach. Complex 6 features an unusual κ(1)-N,κ(2)-O,η(6)-arene coordination mode of the amidinate ligand onto Yb(II). Complexes 7 and 8 represent the first examples of lanthanide complexes with π-coordination of carbazol-9-yl ligands. Complexes 6 and 7, as well as the amidinate-Yb(II)-amide [tBuC(NC6H3-iPr2-2,6)2]YbN(SiMe3)2(THF) (5), are efficient precatalysts for the intermolecular hydrophosphination and hydroamination of styrene with diphenylphosphine, phenylphosphine, and pyrrolidine to give exclusively the anti-Markovnikov monoaddition product. For both types of reaction, the best performances were observed with carbazol-9-yl complex 7 (TONs up to 92 and 48 mol/mol at 60 °C, respectively).
Rare-earth dichloro and bis(alkyl) complexes supported by bulky amido-imino ligand. Synthesis, structure, reactivity and catalytic activity in isoprene polymerization. - Dalton transactions (Cambridge, England : 2003)
A monoanionic amido-imino ligand system [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)](-) was successfully employed for the synthesis of monomeric dichloro [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)]LnCl2(THF)2 (Ln = Y, 2Y; Lu, 2Lu) and bis(alkyl) [(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)]Ln(CH2SiMe3)2(THF) (Ln = Y, 4Y; Lu, 4Lu) species of yttrium and lutetium. Dichloro complexes 2Y and 2Lu turned out to be unstable in aromatic solvents. The ligand symmetrization reaction in the case of 2Y affords the yttrium complex coordinated by dianionic [(2,6-iPr2C6H3)NC(=CH2)C(=CH2)N(C6H3-2,6-iPr2)](2-) ligand, (2,6-iPr2C6H3)N=C(Me)C(Me)=N(C6H3-2,6-iPr2) and YCl3. On the contrary, bis(alkyl) species 4Y and 4Lu are rather stable and do not undergo such a transformation or thermal decomposition. The treatment of complex 4Y with DME resulted in C-O bond cleavage and the formation of a dimeric methoxy-alkyl species {[(2,6-iPr2C6H3)N=C(Me)C(=CH2)N(C6H3-2,6-iPr2)]Y(CH2SiMe3)(μ-OMe)}2 (5). The ternary systems 4Ln/AliBu3/borate (borate = [HNMe2Ph][B(C6F5)4] and [CPh3][B(C6F5)4]; molar ratio 1 : 10 : 1) performed high catalytic activity in isoprene polymerization and ability to convert into polymer 1000-5000 equivalents of isoprene in 20-120 min with quantitative conversion. The obtained polyisoprenes possessed high molecular weights (2.9 × 10(4)-4.1 × 10(4)) and moderate polydispersities (2.14-3.52). Predominant 3,4-regioselectivity (up to 78%) was observed.
LiCl-effect on asymmetric intramolecular hydroamination catalyzed by binaphthylamido yttrium complexes. - Dalton transactions (Cambridge, England : 2003)
Chiral alkyl or amido yttrium complexes were prepared from N-silyl- or N-cyclopentyl-substituted binaphthylamido ligands. According to the synthetic procedure, these complexes could be obtained in their neutral form or as heterobimetallic complexes in the presence of 1 equiv. LiCl. These new species were characterized by IR and NMR spectroscopies, elemental analyses and some of them by X-ray diffraction studies. Their efficiency as catalysts for the asymmetric intramolecular hydroamination was then evaluated with several substrates towards the synthesis of two pyrrolidines and a piperidine derivative. A cooperative effect between the lithium and the yttrium atoms was undoubtedly revealed. LiCl-containing complexes afforded indeed higher enantioselectivities than their salt-free counterparts and according to the structure of the chiral ligand, they were also the most active species.
A double addition of Ln-H to a carbon-carbon triple bond and competitive oxidation of ytterbium(II) and hydrido centers. - Angewandte Chemie (International ed. in English)
Addition of two Ln-H bonds of an Yb(II) hydrido complex supported by bulky amidinate ligand to a C≡C bond lead to the formation of 1,2-dianionic bibenzyl fragment. Both Yb(II) and hydrido centers are oxidized under the reaction conditions. The resulting Yb(II)-η(6) -arene interaction is surprisingly robust: the arene cannot be replaced from the metal coordination sphere when treated with Lewis bases.Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Bis(guanidinate) alkoxide complexes of lanthanides: synthesis, structures and use in immortal and stereoselective ring-opening polymerization of cyclic esters. - Chemistry (Weinheim an der Bergstrasse, Germany)
A series of new bis(guanidinate) alkoxide Group 3 metal complexes [Ln((Me3Si)2NC(NiPr)2)2(OR)] (R=OtBu, Ln=Y, Nd, Sm, Lu; R=OiPr, Ln=Y, Nd, Lu) has been synthesized. X-ray structural determinations revealed that bis(guanidinate) tert-butoxides are monomeric complexes. The isopropoxide complex [Y((Me3Si)2NC(NiPr)2)2(OiPr)] undergoes slow decomposition in solution, to afford the unusual dimeric amido complex [(Y((Me3Si)2NC(NiPr)2)2(mu-N(iPr)C triple chemical bond N))2]. Complexes [Ln((Me3Si)2NC(NiPr)2)2(OR)] (R=OtBu, Ln=Y, Nd, Sm, Lu; R=OiPr, Ln=Y, Nd, Lu) are active catalysts/initiators for the ROP of rac-lactide and rac-beta-butyrolactone under mild conditions. Most of those polymerizations proceed with a significant degree of control. Bis(guanidinate) alkoxides appear to be well suited for achieving immortal polymerization of lactide, through the introduction of large amounts of isopropanol as a chain-transfer agent. The synthesized complexes are able to promote the stereoselective ROP of rac-beta-butyrolactone to afford syndiotactic poly(hydrobutyrate) through a chain-end control mechanism, while they are surprisingly non-stereoselective for the ROP of lactide under strictly similar conditions.
New chiral lanthanide amide ate complexes for the catalysed synthesis of scalemic nitrogen-containing heterocycles. - Chemistry (Weinheim an der Bergstrasse, Germany)
New chiral binaphthylamido yttrium and ytterbium ate complexes with lithium and potassium counterions have been synthesised and characterised. X-ray structures have been obtained for [Li(thf)4][Ln{(R)-C20H12(NC5H9)2}2] (Ln=Yb, Y) and [K(thf)5][Yb{(R)-C20H12(NCH2CMe3)2}2] as isostructural complexes. The efficiency of these complexes for the enantioselective intramolecular hydroamination was examined. [Li(thf)4][Yb{(R)-C20H12(NC5H9)2}2] afforded the highest enantiomeric excess (up to 87 %) for the synthesis of a spiropyrrolidine, while [Li(thf)4][Y{(R)-C20H12(NC5H9)2}2] proved to be slightly more active. The role of the counter cation in the active catalytic species was evidenced by the comparison between lithium and potassium ate complexes. The most active catalyst of this series, [Li(thf)4][Yb{(R)-C20H12(NCH2CMe3)2}2], was successfully used for the cyclisation of aminopentenes with internal double bonds.

Map & Directions

260 Avenue X Brooklyn, NY 11223
View Directions In Google Maps

Nearby Doctors

79 Avenue U
Brooklyn, NY 11223
718 736-6706
1777 Ocean Pkwy
Brooklyn, NY 11223
718 989-9114
49 Bokee Ct Apt 3A
Brooklyn, NY 11223
718 507-7242
219 Avenue U
Brooklyn, NY 11223
718 965-5790
191 Ave V
Brooklyn, NY 11223
718 732-2828
415 Avenue P Lower Level
Brooklyn, NY 11223
917 152-2299
2020 Coney Island Ave Brooklyn
Brooklyn, NY 11223
718 764-4202
372 Avenue U 2Nd Floor
Brooklyn, NY 11223
718 985-5100
445 Kings Hwy First Floor
Brooklyn, NY 11223
718 452-2201